Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Autoren:: Richard Kefford, Ryan J Sullivan, Wilson H Miller Jr, Elena M Elez, Daniel Tan, Kevin B Kim, Georgina V Long, Keith T Flaherty, David Tai, Simone Stutvoet, Heiko Maacke, Matt Whiley, Laure Moutouh-de Parseval, Josep Tabernero

Without Abstract

Titel: Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
Autoren:: Richard Kefford
Ryan J Sullivan
Wilson H Miller Jr
Elena M Elez
Daniel Tan
Kevin B Kim
Georgina V Long
Keith T Flaherty
David Tai
Simone Stutvoet
Heiko Maacke
Matt Whiley
Laure Moutouh-de Parseval
Josep Tabernero
Publikationsdatum: 01.05.2014
DOI: https://doi.org/10.1186/1479-5876-12-S1-P5
Verlag: BioMed Central
Zeitschrift: Journal of Translational Medicine
Ausgabe Sonderheft 1/2014
Elektronische ISSN: 1479-5876